Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial (SPCG-12) (2018)

Peer-Reviewed Study · Ahlgren GM, Flodgren P, Tammela TLJ, Kellokumpu-Lehtinen P, Borre M, Angelsen A, Iversen JR, Sverrisdottir A, Jonsson E, Sengelov L; Investigators of the Scandinavian Prostate Cancer Study Number 12 · June 2018

Ahlgren GM et al., 2018-06: SPCG-12 randomised 459 men to six cycles of adjuvant docetaxel or surveillance after radical prostatectomy for high-risk disease. The 5-year risk of progression was 45% with docetaxel vs 38% with surveillance (restricted mean survival 43 vs 46 months; p=0.06), and serious adverse events were 116 vs 41.

Docetaxel without hormonal therapy did not significantly improve biochemical disease-free survival after radical prostatectomy.

Abstract (CONCLUSIONS)

Ahlgren GM et al., 2018-06: SPCG-12 randomised 459 men to six cycles of adjuvant docetaxel or surveillance after radical prostatectomy for high-risk disease. The 5-year risk of progression was 45% with docetaxel vs 38% with surveillance (restricted mean survival 43 vs 46 months; p=0.06), and serious adverse events were 116 vs 41. Funder: not disclosed in the public abstract; full text is paywalled at Elsevier – the European Urology funding and disclosure statements were not accessible in this run, and no industry sponsor is named in the abstract. Maker: docetaxel (Sanofi's Taxotere) given as 75 mg/m2 every 3 weeks. Comparator: surveillance (no treatment). Note the direction of the point estimate favours surveillance; the authors call the difference nonsignificant. Study type: randomized trial.